Key Points
- ANI VP Meredith Cook sold 400 shares on December 12 at an average price of $82.32 for $32,928, reducing her stake by 0.53% to 74,874 shares valued at about $6.16 million.
- ANI reported a strong recent quarter with $2.04 EPS (vs. $1.74 est.) and revenue of $227.8 million (up 53.6% YoY), and set FY2025 guidance of 7.370–7.640 EPS.
- Wall Street sentiment is broadly positive with a consensus "Buy" rating and a consensus target of $102.14, while the stock trades around $80.39 with a market cap of $1.81 billion and a P/E of 49.32.
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Get Free Report) VP Meredith Cook sold 400 shares of the company's stock in a transaction on Friday, December 12th. The shares were sold at an average price of $82.32, for a total value of $32,928.00. Following the completion of the transaction, the vice president directly owned 74,874 shares in the company, valued at approximately $6,163,627.68. This trade represents a 0.53% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
Meredith Cook also recently made the following trade(s):
- On Thursday, November 13th, Meredith Cook sold 400 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $87.27, for a total value of $34,908.00.
- On Monday, October 13th, Meredith Cook sold 400 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $90.09, for a total transaction of $36,036.00.
ANI Pharmaceuticals Trading Down 2.1%
Shares of ANIP stock opened at $80.39 on Friday. ANI Pharmaceuticals, Inc. has a 1-year low of $52.50 and a 1-year high of $99.50. The firm has a market cap of $1.81 billion, a PE ratio of 49.32 and a beta of 0.48. The company has a 50-day moving average of $87.61 and a two-hundred day moving average of $80.54. The company has a debt-to-equity ratio of 1.20, a current ratio of 2.58 and a quick ratio of 2.04.
ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last issued its quarterly earnings data on Friday, November 7th. The specialty pharmaceutical company reported $2.04 EPS for the quarter, topping the consensus estimate of $1.74 by $0.30. The firm had revenue of $227.81 million for the quarter, compared to analyst estimates of $211.92 million. ANI Pharmaceuticals had a net margin of 4.91% and a return on equity of 26.73%. The business's revenue for the quarter was up 53.6% compared to the same quarter last year. During the same period in the prior year, the business posted $1.34 EPS. ANI Pharmaceuticals has set its FY 2025 guidance at 7.370-7.640 EPS. On average, analysts predict that ANI Pharmaceuticals, Inc. will post 3.86 EPS for the current year.
Wall Street Analysts Forecast Growth
ANIP has been the subject of several research analyst reports. Truist Financial raised their price target on ANI Pharmaceuticals from $77.00 to $90.00 and gave the stock a "hold" rating in a research report on Thursday, October 9th. Guggenheim increased their target price on ANI Pharmaceuticals from $114.00 to $115.00 and gave the stock a "buy" rating in a research note on Monday, November 10th. Zacks Research raised ANI Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research report on Thursday, August 21st. Barclays assumed coverage on shares of ANI Pharmaceuticals in a research note on Tuesday. They set an "overweight" rating and a $100.00 price target on the stock. Finally, HC Wainwright increased their price target on shares of ANI Pharmaceuticals from $93.00 to $121.00 and gave the stock a "buy" rating in a research report on Wednesday, September 17th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus target price of $102.14.
Check Out Our Latest Report on ANIP
Institutional Trading of ANI Pharmaceuticals
Large investors have recently made changes to their positions in the company. Charles Schwab Investment Management Inc. lifted its stake in ANI Pharmaceuticals by 0.9% in the first quarter. Charles Schwab Investment Management Inc. now owns 238,377 shares of the specialty pharmaceutical company's stock worth $15,959,000 after acquiring an additional 2,220 shares during the last quarter. National Bank of Canada FI acquired a new stake in shares of ANI Pharmaceuticals in the 1st quarter valued at $79,000. Connor Clark & Lunn Investment Management Ltd. lifted its position in shares of ANI Pharmaceuticals by 202.7% during the 1st quarter. Connor Clark & Lunn Investment Management Ltd. now owns 46,750 shares of the specialty pharmaceutical company's stock worth $3,130,000 after purchasing an additional 31,308 shares during the last quarter. Invesco Ltd. lifted its position in shares of ANI Pharmaceuticals by 1.0% during the 1st quarter. Invesco Ltd. now owns 199,567 shares of the specialty pharmaceutical company's stock worth $13,361,000 after purchasing an additional 2,022 shares during the last quarter. Finally, Nuveen LLC acquired a new position in shares of ANI Pharmaceuticals during the first quarter worth $3,254,000. 76.05% of the stock is currently owned by hedge funds and other institutional investors.
ANI Pharmaceuticals Company Profile
(
Get Free Report)
ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
